At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 51 enrolled
Drug / intervention
Adapalene +1 moredrug
Likely dose
Adapalene 2gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pharmacokinetic Study to Compare the Systemic Exposure to Adapalene During Dermal Application of Either Differin® Gel, 0.3% (Adapalene 0.3%) or Differin® Gel, 0.1% (Adapalene 0.1%) for 30 Days in Subjects With Acne Vulgaris
In Brief
A Phase 4 clinical trial evaluating Adapalene for Acne Vulgaris. Completed, enrolled 51 participants across 2 sites.
Detailed Summary
Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartMay 2008
Primary CompletionAug 2008
Study CompletionNov 2008
TodayJul 2026
First PostedApr 18, 2008
Enrollment StartMay 1, 2008
Primary CompletionAug 1, 2008
Study CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.2 years ago
Interventions
Adapalenedrug
Gel, 0.3%, 2g, once daily for 30 days
Adapalenedrug
Gel, 0.1%, 2g, once daily for 30 days